ERBB2 and triple-negative breast carcinoma: HR-/HER2+ tumors demonstrated the highest predicted pCR probability at 71.8%, followed by triple-negative breast cancer at 62.4% (Tables 4, Table 5), supporting current guidelines recommending NAC for these subtypes as opposed to luminal A and B subtypes [23-25].